IBDEI0EI ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6619,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,6620,0)
 ;;=238.6^^31^412^107
 ;;^UTILITY(U,$J,358.3,6620,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6620,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,6620,1,5,0)
 ;;=5^Plasmacytoma MOS
 ;;^UTILITY(U,$J,358.3,6620,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,6621,0)
 ;;=205.00^^31^412^3
 ;;^UTILITY(U,$J,358.3,6621,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6621,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,6621,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,6621,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,6622,0)
 ;;=205.01^^31^412^4
 ;;^UTILITY(U,$J,358.3,6622,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6622,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,6622,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,6622,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,6623,0)
 ;;=205.10^^31^412^15
 ;;^UTILITY(U,$J,358.3,6623,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6623,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,6623,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,6623,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,6624,0)
 ;;=205.11^^31^412^16
 ;;^UTILITY(U,$J,358.3,6624,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6624,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,6624,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,6624,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,6625,0)
 ;;=289.0^^31^412^54
 ;;^UTILITY(U,$J,358.3,6625,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6625,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,6625,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,6625,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,6626,0)
 ;;=238.4^^31^412^108
 ;;^UTILITY(U,$J,358.3,6626,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6626,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,6626,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,6626,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,6627,0)
 ;;=V58.61^^31^412^123
 ;;^UTILITY(U,$J,358.3,6627,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6627,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,6627,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,6627,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,6628,0)
 ;;=282.49^^31^412^113
 ;;^UTILITY(U,$J,358.3,6628,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6628,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,6628,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,6628,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,6629,0)
 ;;=289.89^^31^412^12
 ;;^UTILITY(U,$J,358.3,6629,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6629,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,6629,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,6629,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,6630,0)
 ;;=238.79^^31^412^86
 ;;^UTILITY(U,$J,358.3,6630,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6630,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,6630,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis NEC
 ;;^UTILITY(U,$J,358.3,6630,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,6631,0)
 ;;=287.30^^31^412^109
 ;;^UTILITY(U,$J,358.3,6631,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6631,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,6631,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,6631,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,6632,0)
 ;;=288.09^^31^412^5
 ;;^UTILITY(U,$J,358.3,6632,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6632,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,6632,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,6632,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,6633,0)
 ;;=V10.21^^31^412^60
 ;;^UTILITY(U,$J,358.3,6633,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6633,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,6633,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;
 ;;$END ROU IBDEI0EI
